Sun Pharma and Ferring Pharmaceuticals to introducing CARITEC in India
Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name CARITEC
Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name CARITEC
For undertaking production, the company has been provided a Rs. 65 crore grant by the centre and Rs. 94 crore from the government of Maharashtra
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
Aurobindo has one of the most enduring generics ecosystems among peers
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
The company reported total income of Rs.24774.63 crores during the 12 months period ended March 31, 2021
It posted net profit of Rs.60.96 crores for the 12 months period ended March 31, 2021
Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
Subscribe To Our Newsletter & Stay Updated